SOURCE: Active Biotech

May 15, 2008 04:21 ET

Active Biotech to Present at the Rodman & Renshaw 5th Annual Global Healthcare Conference

LUND, SWEDEN--(Marketwire - May 15, 2008) - Lund, Sweden - 15 May 2008 - Active Biotech (OMX Nordic: ACTI) management is scheduled to present at the Rodman & Renshaw Annual Global Healthcare Conference next week at 10:00 AM CEST on Tuesday, 20 May at Le Meridien Beach Plaza Hotel, Monte Carlo, Monaco. During the presentation, an update will be provided on the Active Biotech development program.

The company has five projects in clinical development for the treatment of serious autoimmune/inflammatory diseases and cancer. Laquinimod - a novel oral treatment of multiple sclerosis - is developed through a cooperation with Teva Pharmaceutical Industries Ltd and is currently in Phase III global clinical trials in US, Europe and Israel with approximately 2 200 patients. ANYARA - a novel cancer targeted therapy - is in Phase III trials with 500 advanced renal cell cancer patients. Further key projects in clinical development comprise three orally administered compounds; TASQ for prostate cancer in Phase II, 57-57 for Systemic Lupus Erythematosus (SLE) in Phase Ib and RhuDex® (licensed to MediGene AG) for Rheumatoid Arthritis (RA) in Phase IIa.

The Active Biotech audio and slide presentation will be web cast live on 20 May, at 10:00 AM CEST. A replay will be available approximately two hours following the presentation and archived on the company's web site. To access the live and replay presentations, visit the Active Biotech web site -

The complete Conference Schedule can be accessed at:

Active Biotech AB is a biotechnology company focusing on research and development of pharmaceuticals. Active Biotech has a strong R&D portfolio with pipeline products focused on autoimmune/inflammatory diseases and cancer. Most advanced projects are laquinimod, an orally administered small molecule with unique immunomodulatory properties for the treatment of multiple sclerosis, as well as ANYARA for use in cancer targeted therapy, the primary indication being renal cancer. Further key projects in clinical development comprise the three orally administered compounds TASQ for prostate cancer, 57-57 for SLE and RhuDex® for RA.

Active Biotech AB
Cecilia Hofvander
P.O. Box 724, SE-220 07 Lund, Sweden
Tel: +46 (0)46-19 20 00
Direct: +46 (0)46 19 11 22
Fax: +46 (0)46-19 20 50

Copyright © Hugin AS 2008. All rights reserved.

Contact Information